Bladder cancer in renal allograft recipients: Risk factors and outcomes

Transplantation Proceedings

Volumn 46, Issue 10, 2014, Pages 3466-3473

  Medani, S ^a   O'Kelly, P ^a   O'Brien, K M ^b   Mohan, P ^a   Magee, C ^a   Conlon, P ^a  

^a BEAUMONT HOSPITAL   (Ireland)

^b NATIONAL CANCER REGISTRY IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANALGESIC NEPHROPATHY; ARTICLE; BLADDER CANCER; BLADDER CARCINOMA; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTECTOMY; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRELAND; KIDNEY ALLOGRAFT; LARGE CELL LYMPHOMA; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMOKING; SQUAMOUS CELL CARCINOMA; STANDARDIZED INCIDENCE RATIO; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; ADVERSE EFFECTS; ALLOTRANSPLANTATION; INCIDENCE; KIDNEY TRANSPLANTATION; MIDDLE AGED; REGISTER; RISK FACTOR; SURVIVAL RATE; TRENDS; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOSUPPRESSION; INCIDENCE; IRELAND; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; URINARY BLADDER NEOPLASMS;

EID: 84926348433     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2014.06.075     Document Type: Article

References (60)

1. Mazuecos A, Muñoz Terol JM, García Alvárez T, et al. Increase in malignancies as cause of death in renal transplant patients. Transplant Proc 2009;41:2159-62.
2. Pilmore H, Dent H, Chang S, et al. Reduction in cardiovascular death after kidney transplantation. Transplantation 2010;89: 851-7.
3. Knoll G, Cockfield S, Blydt-Hansen T, et al. Canadian Society of Transplantation: Consensus guidelines on eligibility for kidney transplantation. Can Med Assoc J 2005;173:S1-25.
4. Caring for Australasians With Renal Impairment. KHACARI guidelines. Available at: http://www.cari.org.au/TRANS- recipient-assessment/Malignancy-31-Aug-2011.
5. Kasiske BL, Cangro CB, Hariharan S, et al. The evaluation of renal transplantation candidates: Clinical practice guidelines. Am J Transplant 2001;1(suppl 2):3-95.
6. Morath C, Mueller M, Goldschmidt H, et al. Malignancy in renal transplantation. J Am Soc Nephrol 2004;15:1582-8.
7. Tuttle TM, Williams GM, Marshall FF. Evidence for cyclophosphamide-induced transitional cell carcinoma in a renal transplant patient. J Urol 1988;140:1009-11.
8. Lemmers MJ, Barry JM. De novo carcinoma of the lower urinary tract in renal allograft recipients. J Urol 1990;144:1233-5.
9. Lam KY, Chan KW, Lo WK. Bladder carcinoma in a renal transplant patient. Br J Urol 1993;72:511-3.
10. Thon WF, Kliem V, Truss MC, et al. De-novo urothelial carcinoma of the upper and lower urinary tract in kidneyd transplant patients with end-stage analgesic nephropathy. World J Urol 1995;13:254-61.
11. Wang HB, Hsieh HH, Chen YT, et al. The outcome of posttransplant transitional cell carcinoma in 10 renal transplant patients. Clin Transplant 2001;16:410-3.
12. Kao YL, Ou YC, Yang CR, et al. Transitional cell carcinoma in renal transplant recipients. World J Surg 2003;27: 912-6.
13. Master VA, Meng MV, Grossfeld GD, et al. Treatment and outcome of invasive bladder cancer in patients after renal transplantation. J Urol 2004;171:1085-8.
14. Liao CH, Chueh SC, Lai MK, et al. Transitional cell carcinoma in renal transplant recipients. Transplant Proc 2004;36: 2152-3.
15. Wu MJ, Lian JD, Yang CR, et al. High cumulative incidence of transitional cell carcinoma after kidney transplantation in Taiwan. Am J Kidney Dis 2004;43:1091-7.
16. Diller R, Gruber A, Wolters H, et al. Therapy and prognosis of tumors of the genitourinary tract after kidney transplantation. Transplant Proc 2005;37:2089-92.
17. Kamal MM, Soliman SM, Shokeir AA, et al. A. Bladder carcinoma among live-donor renal transplant recipients: A singlecentre experience and a review of the literature. BJU Int 2008;101:30-5.
18. Besarani D, Cranston D. Urological malignancy after renal transplantation. BJU Int 2007;100:502-5.
19. Villeneuve PJ, Schaubel DE, Fenton SS, et al. Cancer incidence among Canadian kidney transplant recipients. Am J Transplant 2007;7:941-8.
20. Li XB, Xing NZ, Wang Y, et al. Transitional cell carcinoma in renal transplant recipients: A single center experience. Int J Urol 2008;15:53-7.
21. Ehdaie B, Stukenborg GJ, Theodorescu D. Renal transplant recipients and patients with end stage renal disease present with more advanced bladder cancer. J Urol 2009;182:1482-7.
22. Einollahi B, Simforoosh N, Lessan-Pezeshki M, et al. Genitourinary tumor following kidney transplantation: A multicenter study. Transplant Proc 2009;41:2848-9.
23. Elkentaoui H, Robert G, Pasticier G, et al. Therapeutic management of de novo urological malignancy in renal transplant recipients: The experience of the French Department of Urology and Kidney Transplantation from Bordeaux. Urology 2010;75: 126-33.
24. Tsaur I, Karalis A, Probst M, et al. Development of urological cancers in renal transplant recipients: 30 year experience at the Frankfurt Transplant Center. Cancer Sci 2010;101: 2430-5.
25. Melchior S, Franzaring L, Shardan A, et al. Urological de novo malignancy after kidney transplantation: A case for the urologist. J Urol 2011;185:428-32.
26. Hwang JK, Moon IS, Kim JI. Malignancies after kidney transplantation: A 40-year single-center experience in Korea. Transpl Int 2011;24:716-21.
27. Cox J, Colli JL. Urothelial cancers after renal transplantation. Int Urol Nephrol 2011;43:681-6.
28. Tomaszewski JJ, Larson JA, Smaldone MC, et al. Management of bladder cancer following solid organ transplantation. Adv Urol 2011;2011:256985.
29. Li WH, Chen YJ, Tseng WC, et al. Malignancies after renal transplantation in Taiwan: A nationwide population-based study. Nephrol Dial Transplant 2012;27:833-9.
30. Chiang YJ, Yang PS, Wang H, et al. Urothelial cancer after renal transplantation: An update. Transplant Proc 2012;44:744-5.
31. Cheung CY, Lam MF, Chu KH. Malignancies after kidney transplantation: Hong Kong Renal Registry. Am J Transplant 2012;12:3039-46.
32. Rogers A, Koo Ng J, Glendinning J, et al. The management of transitional cell carcinoma (TCC) in a European regional renal transplant population. BJU Int 2012;110:E34-40.
33. Miao Y, Everly JJ, Gross TG, et al. De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation 2009;87: 1347-59.
34. Davis NF, McLoughlin LC, Dowling C, et al. Incidence and long-term outcomes of squamous cell bladder cancer after deceased donor renal transplantation. Clin Transplant 2013;27:E665-8.
35. Kunze E, Chang-Claude J, Frentzel-Beyme R. Life style and occupational risk factors for bladder cancer in Germany: A casecontrol study. Cancer 1992;69:1776-90.
36. Reulen RC, Kellen E, Buntinx F, et al. A meta-analysis on the association between bladder cancer and occupation. Scand J Urol Nephrol Suppl 2008;218:64-78.
37. Rivera CF, Hernández ÁA, Reboredo JM, et al. Association of bladder adenocarcinoma and BK virus infection in a pancreaticorenal transplant recipient. Nephrol Dial Trans Plus 2010;3:300-2.
38. van Aalderen MC, Yapici Ü, van der Pol JA, et al. Polyomavirus BK in the pathogenesis of bladder cancer. Neth J Med 2013;71:26-8.
39. Alexiev BA, Randhawa P, Vazquez Martul E, et al. BK viruseassociated urinary bladder carcinoma in transplant recipients: Report of 2 cases, review of the literature, and proposed pathogenetic model. Hum Pathol 2012;44:908-17.
40. Li N, Yang L, Zhang Y, et al. Human papillomavirus infection and bladder cancer risk: A meta-analysis. J Infect Dis 2011;204:217-23.
41. La Vecchia C, Negri E, D'Avanzo B, et al. Genital and urinary tract diseases and bladder cancer. Cancer Res 1991;51:629-31.
42. Weng PH, Hung KY, Huang HL, et al. Cancer-specific mortality in chronic kidney disease: longitudinal follow-up of a large cohort. Clin J Am Soc Nephrol 2011;6:1121-8.
43. Stewart JH, Buccianti G, Agodoa L, et al. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: Analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol 2003;14: 197-207.
44. Cengiz K. Increased incidence of neoplasia in chronic renal failure (20-year experience). Int Urol Nephrol 2002;33:121-6.
45. Mandayam S, Shahinian VB. Are chronic dialysis patients at increased risk for cancer? J Nephrol 2008;21:166-74.
46. Stewart JH, Vajdic CM, van Leeuwen MT, et al. The pattern of excess cancer in dialysis and transplantation. Nephrol Dial Transplant 2009;24:3225-31.
47. Lin HF, Li YH, Wang CH, et al. Increased risk of cancer in chronic dialysis patients: A population-based cohort study in Taiwan. Nephrol Dial Transplant 2012;27:1585-90.
48. Gonwa TA, Corbett WT, Schey HM, et al. Analgesic-associated nephropathy and transitional cell carcinoma of the urinary tract. Ann Intern Med 1980;93:249-52.
49. Kang D, Chokkalingam AP, Gridley G, et al. Benign prostatic hyperplasia and subsequent risk of bladder cancer. Br J Cancer 2007;96:1475-9.
50. Tseng CH. Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: A population-based cohort study using the National Health Insurance in Taiwan. BMC Cancer 2013;13:7.
51. Nortier JL, Martinez MCM, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (aristolochia fangchi). N Engl J Med 2000;342:1686-92.
52. Chiou HY, Chiou ST, Hsu YH, et al. Incidence of transitional cell carcinoma and arsenic in drinking water: A follow-up study of 8102 residents in an arseniasis-endemic area in northeastern Taiwan. Am J Epidemiol 2001;153:411-8.
53. Chiang YJ, Chu SH, Liu KL, et al. Silent urothelial cancer detected by sonography after renal transplantation. Transplant Proc 2006;38:2084-5.
54. Palou J, Angerri O, Segarra J, et al. Intravesical bacillus Calmette-Guèrin for the treatment of superficial bladder cancer in renal transplant patients. Transplantation 2003;76:1514-6.
55. Prabharasuth D, Moses KA, Bernstein M, et al. Management of bladder cancer after renal transplantation. Urology 2013;81:813-9.
56. Deresiewicz RL, Stone RM, Aster JC. Fatal disseminated mycobacterial infection following intravesical bacillus Calmette-Guerin. J Urol 1990;144:1331-3.
57. Rawls WH, Lamm DL, Lowe BA, et al. Fatal sepsis following intravesical bacillus CalmetteeGuerin administration for bladder cancer. J Urol 1990;144:1328-30.
58. Power RE, Hickey DP, Little DM. Urological evaluation prior to renal transplantation. Transplant Proc 2004;36:2962-7.
59. Karczewski M, Czapiewski W, Karczewski J. Urologic de novo malignancies after kidney transplantation: A single center experience. Transplant Proc 2012;44:1293-7.
60. Tai HC, Lai MK, Wang SM, et al. High incidence of urinary tract malignancy among patients with hematuria following kidney transplantation in Taiwan. Transpl Int 2009;22:403-7.